Your browser doesn't support javascript.
loading
Prediagnostic alterations in circulating bile acid profiles in the development of hepatocellular carcinoma.
Stepien, Magdalena; Lopez-Nogueroles, Marina; Lahoz, Agustin; Kühn, Tilman; Perlemuter, Gabriel; Voican, Cosmin; Ciocan, Dragos; Boutron-Ruault, Marie-Christine; Jansen, Eugene; Viallon, Vivian; Leitzmann, Michael; Tjønneland, Anne; Severi, Gianluca; Mancini, Francesca Romana; Dong, Catherine; Kaaks, Rudolf; Fortner, Renee Turzanski; Bergmann, Manuela M; Boeing, Heiner; Trichopoulou, Antonia; Karakatsani, Anna; Peppa, Eleni; Palli, Domenico; Krogh, Vittorio; Tumino, Rosario; Sacerdote, Carlotta; Panico, Salvatore; Bueno-de-Mesquita, H Bas; Skeie, Guri; Merino, Susana; Ros, Raul Zamora; Sánchez, Maria Jose; Amiano, Pilar; Huerta, Jose Mª; Barricarte, Aurelio; Sjöberg, Klas; Ohlsson, Bodil; Nyström, Hanna; Werner, Marten; Perez-Cornago, Aurora; Schmidt, Julie A; Freisling, Heinz; Scalbert, Augustin; Weiderpass, Elisabete; Christakoudi, Sofia; Gunter, Marc J; Jenab, Mazda.
Afiliação
  • Stepien M; Nutrition and Metabolism Branch (NME), International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Lopez-Nogueroles M; Analytical Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
  • Lahoz A; Analytical Unit, Health Research Institute Hospital La Fe, Valencia, Spain.
  • Kühn T; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Perlemuter G; INSERM U996, Intestinal Microbiota, Macrophages and Liver Inflammation, DHU Hepatinov, Labex LERMIT, Clamart, France.
  • Voican C; Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Ciocan D; Service d'hépato-Gastroentérologie, Hôpital Antoine-Béclère, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France.
  • Boutron-Ruault MC; INSERM U996, Intestinal Microbiota, Macrophages and Liver Inflammation, DHU Hepatinov, Labex LERMIT, Clamart, France.
  • Jansen E; Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Viallon V; Service d'hépato-Gastroentérologie, Hôpital Antoine-Béclère, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France.
  • Leitzmann M; INSERM U996, Intestinal Microbiota, Macrophages and Liver Inflammation, DHU Hepatinov, Labex LERMIT, Clamart, France.
  • Tjønneland A; Faculté de Médecine Paris-Sud, Université Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
  • Severi G; Service d'hépato-Gastroentérologie, Hôpital Antoine-Béclère, Hôpitaux Universitaires Paris-Sud, Assistance Publique-Hôpitaux de Paris, Clamart, France.
  • Mancini FR; CESP, Faculté de Médecine-Université Paris-Saclay, Faculté de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Dong C; Gustave Roussy, Villejuif, France.
  • Kaaks R; National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Fortner RT; Nutrition and Metabolism Branch (NME), International Agency for Research on Cancer (IARC-WHO), Lyon, France.
  • Bergmann MM; Department of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany.
  • Boeing H; Diet, Genes and Environment Unit, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Trichopoulou A; CESP, Faculté de Médecine-Université Paris-Saclay, Faculté de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Karakatsani A; Gustave Roussy, Villejuif, France.
  • Peppa E; CESP, Faculté de Médecine-Université Paris-Saclay, Faculté de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Palli D; Gustave Roussy, Villejuif, France.
  • Krogh V; CESP, Faculté de Médecine-Université Paris-Saclay, Faculté de Médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
  • Tumino R; Gustave Roussy, Villejuif, France.
  • Sacerdote C; Department of Gastroenterology, Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
  • Panico S; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bueno-de-Mesquita HB; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Skeie G; Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany.
  • Merino S; Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbrücke, Germany.
  • Ros RZ; Hellenic Health Foundation, Athens, Greece.
  • Sánchez MJ; Hellenic Health Foundation, Athens, Greece.
  • Amiano P; 2nd Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, "ATTIKON" University Hospital, Haidari, Greece.
  • Huerta JM; Hellenic Health Foundation, Athens, Greece.
  • Barricarte A; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network-ISPRO, Florence, Italy.
  • Sjöberg K; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milano, Milan, Italy.
  • Ohlsson B; Department of Cancer Registry and Histopathology, "M.P. Arezzo" Hospital, ASP Ragusa, Ragusa, Italy.
  • Nyström H; Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy.
  • Werner M; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  • Perez-Cornago A; Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
  • Schmidt JA; Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands.
  • Freisling H; Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London, UK.
  • Scalbert A; Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
  • Weiderpass E; Department of Community Medicine, UIT-The Arctic University of Norway, Tromsø, Norway.
  • Christakoudi S; Public Health Directorate, Asturias, Spain.
  • Gunter MJ; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
  • Jenab M; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA, Universidad de Granada, Granada, Spain.
Int J Cancer ; 150(8): 1255-1268, 2022 04 15.
Article em En | MEDLINE | ID: mdl-34843121
ABSTRACT
Bile acids (BAs) play different roles in cancer development. Some are carcinogenic and BA signaling is also involved in various metabolic, inflammatory and immune-related processes. The liver is the primary site of BA synthesis. Liver dysfunction and microbiome compositional changes, such as during hepatocellular carcinoma (HCC) development, may modulate BA metabolism increasing concentration of carcinogenic BAs. Observations from prospective cohorts are sparse. We conducted a study (233 HCC case-control pairs) nested within a large observational prospective cohort with blood samples taken at recruitment when healthy with follow-up over time for later cancer development. A targeted metabolomics method was used to quantify 17 BAs (primary/secondary/tertiary; conjugated/unconjugated) in prediagnostic plasma. Odd ratios (OR) for HCC risk associations were calculated by multivariable conditional logistic regression models. Positive HCC risk associations were observed for the molar sum of all BAs (ORdoubling  = 2.30, 95% confidence intervals [CI] 1.76-3.00), and choline- and taurine-conjugated BAs. Relative concentrations of BAs showed positive HCC risk associations for glycoholic acid and most taurine-conjugated BAs. We observe an association between increased HCC risk and higher levels of major circulating BAs, from several years prior to tumor diagnosis and after multivariable adjustment for confounders and liver functionality. Increase in BA concentration is accompanied by a shift in BA profile toward higher proportions of taurine-conjugated BAs, indicating early alterations of BA metabolism with HCC development. Future studies are needed to assess BA profiles for improved stratification of patients at high HCC risk and to determine whether supplementation with certain BAs may ameliorate liver dysfunction.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / Biomarcadores Tumorais / Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ácidos e Sais Biliares / Biomarcadores Tumorais / Carcinoma Hepatocelular / Neoplasias Hepáticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article